Clinical trials: Grade I Meningioma
Acoustic Schwannoma, Adult Anaplastic Astrocytoma
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
This pilot clinical trial studies gallium Ga 68-edotreotide (68Ga-DOTATOC) positron emission tomography (PET)/computed tomography (CT) in finding brain tumors in younger patients.
- Conditions
- Acoustic Schwannoma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma
- Trial name
- NCT02194452
- Testing
- gallium Ga 68-edotreotide, positron emission tomography, computed tomography
- Where
- United States
- Sponsor
- Sue O'Dorisio
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00053963
- Testing
- romidepsin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Sarcoma
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
RATIONALE: Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00348790
- Testing
- vatalanib
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Brain and Central Nervous System Tumors, Metastatic Cancer
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
RATIONALE: Learning about the side effects of stereotactic radiosurgery in patients with brain tumors or other brain disorders may help doctors plan treatment and help patients live more comfortably.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
- Trial name
- NCT00255671
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Glioma, High-grade Meningioma
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
This is an open label phase I clinical trial with two arms, representing single and fractionated radiation therapy (Figure 4.1). Within each arm the radiation dose is pre-determined and not escalated.
- Conditions
- Recurrent Glioma, High-grade Meningioma, Brain Metastasis
- Trial name
- NCT01324635
- Testing
- Panobinostat, Stereotactic body radiation therapy, Quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00045110
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00138216
- Testing
- irinotecan hydrochloride, temozolomide, vincristine sulfate
- Where
- 18 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors, Lymphoma
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00544284
- Testing
- bortezomib, temozolomide, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors, Leukemia
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00458744
- Testing
- talotrexin, chemotherapy
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors, Metastatic Cancer
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more…
- Trial name
- NCT00784914
- Testing
- temsirolimus, pharmacological study, cytokine levels
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Grade 1 Meningioma, Grade 2 Meningioma
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation…
- Conditions
- Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
- Trial name
- NCT04082520
- Testing
- Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00100880
- Testing
- lenalidomide, perfusion-weighted magnetic resonance imaging, diffusion-weighted magnetic resonance imaging
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Glioma, Meningioma
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET.
- Conditions
- High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma
- Trial name
- NCT05278208
- Testing
- LUTATHERA® (Lutetium Lu 177 dotatate)
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Nationwide Children's Hospital
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Gliomas, Anaplastic Astrocytoma
Cellular Immunotherapy Study for Brain Cancer
The purpose of this research study to determine if treating recurrent malignant gliomas with another person's (donor) immune system cells known as aCTL cells, will be safe.
- Conditions
- Gliomas, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Glioma
- Trial name
- alloCTL (NCT01144247)
- Testing
- alloreactive CTL
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT01076530
- Testing
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Acoustic Schwannoma, Adult Anaplastic Meningioma
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma
- Trial name
- NCT01125046
- Testing
- bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00030108
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Grade 2 Meningioma, Grade 3 Meningioma
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
This phase I/II trial studies the side effects and best dose of nivolumab when given together with multi-fraction stereotactic radiosurgery and to see how well they work with or without ipilimumab in treating patients with grade…
- Conditions
- Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
- Trial name
- NCT03604978
- Testing
- Biospecimen Collection, Echocardiography Test, Ipilimumab
- Where
- 29 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)